Wyden biomaterials inquiry
This article was originally published in The Gray Sheet
Executive Summary
Staffers from Rep. Ron Wyden's (D-Ore.) office request a meeting with FDA officials to discuss biomaterials availability. Wyden had written HHS Secretary Donna Shalala about potential biomaterials shortages in the spring ("The Gray Sheet" May 9, p. 25). Shalala responded that HHS shares "your desire to avoid any needless disruption to the availability of" permanent implants. Acknowledging that "shortages of biomaterials may occur" with potentially "severe" consequences, Shalala outlined "actions taken" by the department that "demonstrate a commitment to ensuring" American leadership in the area of medical technology
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.